Camillo Porta1, Cezary Szczylik2, Roman Casciano3, Shuai Fu4, Billy Amzal5, Johanna Lister6, Helene Karcher7, Jie Meng8, Monika Neumann9, Jerome Dinet10. 1. Department of Internal Medicine, University of Pavia and Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, via S. Maugeri 10, 27100 Pavia, Italy. Electronic address: camillo.porta@unipv.it. 2. Warsaw Medical University, Żwirki i Wigury 61, 02-091 Warsaw, Poland. Electronic address: cszczylik@wp.pl. 3. Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: R.Casciano@analytica-laser.com. 4. Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: S.Fu@analytica-laser.com. 5. Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: B.Amzal@analytica-laser.com. 6. Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: J.Lister@analytica-laser.com. 7. Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: H.Karcher@analytica-laser.com. 8. Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: J.Meng@analytica-laser.com. 9. Analytica Laser, Certara Company, 5th Floor Audrey House, 16-20 Ely Place, London EC1N, UK. Electronic address: M.Neumann@analytica-laser.com. 10. Ipsen Pharma SAS, 65 quai Georges Gorse, Boulogne-Billancourt, Ile-de-France, France. Electronic address: postmaster@jeromedinet.com.
Abstract
BACKGROUND: Nivolumab and cabozantinib, two new treatment options for previously-treated advanced/metastatic renal cell carcinoma (aRCC), have recently been approved. METHODS: Two independent reviewers performed study selection, data extraction, and risk of bias assessment. Indirect treatment comparisons were carried out by directly assessing HR differences and statistical modeling of Kaplan-Meier curves from these two trials. RESULTS: Publications identified showed that no head-to-head comparisons had been carried out. Two indirect treatment comparisons used agreed that there was no significant difference in OS between cabozantinib and nivolumab and that cabozantinib significantly improved PFS compared to nivolumab. CONCLUSIONS: The field of aRCC treatments is evolving rapidly, creating opportunities for individualized treatments and challenges for clinicians to keep up with the evidence. In lieu of availability of direct comparisons of all options, advanced modeling results presented herein can help to inform and improve personalized treatments.
BACKGROUND:Nivolumab and cabozantinib, two new treatment options for previously-treated advanced/metastatic renal cell carcinoma (aRCC), have recently been approved. METHODS: Two independent reviewers performed study selection, data extraction, and risk of bias assessment. Indirect treatment comparisons were carried out by directly assessing HR differences and statistical modeling of Kaplan-Meier curves from these two trials. RESULTS: Publications identified showed that no head-to-head comparisons had been carried out. Two indirect treatment comparisons used agreed that there was no significant difference in OS between cabozantinib and nivolumab and that cabozantinib significantly improved PFS compared to nivolumab. CONCLUSIONS: The field of aRCC treatments is evolving rapidly, creating opportunities for individualized treatments and challenges for clinicians to keep up with the evidence. In lieu of availability of direct comparisons of all options, advanced modeling results presented herein can help to inform and improve personalized treatments.
Authors: Igor Richter; Alexandr Poprach; Anezka Zemankova; Tomas Buchler; Jiri Bartos; Vladimir Samal; Hana Studentova; Aneta Rozsypalova; Josef Dvorak; Ondrej Brom; Bohuslav Melichar Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2020-11-26 Impact factor: 1.245
Authors: Jakub Lagan; Josephine H Naish; Christien Fortune; Christopher Campbell; Shien Chow; Manon Pillai; Joshua Bradley; Lenin Francis; David Clark; Anita Macnab; Gaetano Nucifora; Rebecca Dobson; Erik B Schelbert; Matthias Schmitt; Robert Hawkins; Christopher A Miller Journal: Diagnostics (Basel) Date: 2022-05-30
Authors: Doo Yong Chung; Dong Hyuk Kang; Jong Won Kim; Do Kyung Kim; Joo Yong Lee; Chang Hee Hong; Kang Su Cho Journal: Cancers (Basel) Date: 2019-11-21 Impact factor: 6.639